163
Views
8
CrossRef citations to date
0
Altmetric
Original Article

Diuretics for hypertension – an inconsistency in primary care prescribing behaviour

, , , , , & show all
Pages 497-502 | Accepted 10 Dec 2010, Published online: 06 Jan 2011
 

Abstract

Objective:

Internationally there is an ongoing debate on diuretics as first-line therapy for most patients with hypertension. In spite of many arguments against them in antihypertensive monotherapy, the authors of the present study perceived them to be regularly prescribed in combination therapy in Germany. The study objective was to look for this discrepancy in prescribing reality as a contribution from clinical practice to an academic debate.

Methods:

A descriptive cross-sectional study in a yearly contact group (YCG; 1.7.2007–31.06.2008) was conducted based on data from a scientific network of 22 general practitioners in Germany. All patients with hypertension as diagnosed by their general practitioner were included. Antihypertensives were grouped according to the ATC classification. To assess for potential design effects by the given two-level setting, 95% confidence intervals (CI) were adjusted for clustering.

Results:

Hypertension had been diagnosed in 9.3% of the 58 852 patients. Of these, 21.6% received no antihypertensives. Of those who were treated, 30.6% (CI [28.6–32.6]) had monotherapy. In monotherapy, 8.6% (CI [7.1–10.2]) were prescribed some diuretic, 1.5% (CI [0.5–3.0]) received hydrochlorothiazide (HCT). Combination therapy was prescribed to 69.4% (CI [67.2–71.6]). These patients received some diuretic in 79.0% (CI [76.9–81.0]) of the cases, of which 80.8% (CI [78.5–83.1]) had a combination with HCT. HCT was prescribed in 76.2% (CI [73.5–78.9]) in fixed-dose formulations.

Conclusion:

In spite to the many arguments against them, leading to their almost complete disregard in monotherapy, thiazide-diuretics seem to be standard in combination therapy in Germany. This inconsistency can not be explained by the arguments of the current debate. Key limitations of the present study include the lack of ability to tell whether a given monotherapy is the first-line medication, the small sample size and the possible selection bias.

Transparency

Declaration of funding

The CONTENT-project is supported by the German Ministry of Education and Research (BMBF): Grant-number BMBF 01GK0601. The ministry has no influence on the content of our studies.

Declaration of financial/other interests:

T.K., G.L., A.G., S.C., K.G., J.S. and J.S. have disclosed that they have no relevant financial relationships.

CMRO peer reviewers have disclosed that they have no relevant financial relationships to disclose.

Acknowledgements

The authors would like to thank Rupa Patel from the University of Washington, Seattle (USA) for language corrections.

This study will be presented at the 9th German Congress of Health Services Research at 30. September 2010 in Bonn (Germany), in the German language.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.